Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Avenue Therapeutics, Inc. (ATXI) stock rallied over 1.23% intraday to trade at $0.26 a share on NASDAQ. The stock opened with a gain of 4.00% at $0.267 and touched an intraday high of $0.272, rising 0.00% against the last close of $0.26. The stock went to a low of $0.25 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $0.267 | $0.272 | $0.25 | $0.263 | 355,970 |
2022-07-05 | $0.25 | $0.28 | $0.242 | $0.26 | 111,000 |
2022-07-01 | $0.274 | $0.284 | $0.251 | $0.252 | 217,900 |
2022-06-30 | $0.32 | $0.32 | $0.26 | $0.269 | 531,700 |
2022-06-29 | $0.25 | $0.398 | $0.243 | $0.324 | 3,561,300 |
2022-06-28 | $0.24 | $0.255 | $0.23 | $0.245 | 141,500 |
2022-06-27 | $0.23 | $0.26 | $0.23 | $0.242 | 467,000 |
2022-06-24 | $0.251 | $0.268 | $0.22 | $0.22 | 329,500 |
2022-06-23 | $0.258 | $0.26 | $0.246 | $0.251 | 47,600 |
2022-06-22 | $0.26 | $0.268 | $0.245 | $0.245 | 135,600 |
Employees-
Beta1
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
Avenue Therapeutics, Inc. (NASDAQ: ATXI) stock price is $0.26 as of the last check on Wednesday, July 6. During the trading session, ATXI stock reached the peak price of $0.272 while $0.25 was the lowest point it dropped to.
The NASDAQ listed ATXI is part of Pharmaceuticals industry that operates in the broader Health Care sector. Avenue Therapeutics, Inc. , a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting.
Dr. Xiaoqin Lu M.D.
Pres, CEO & Director
Mr. Joseph Walter Vazzano
CFO, Principal Financial Officer & Company Sec.
Dr. Lindsay Allan Rosenwald
Exec. Chairman
Dr. Xiaoqin Lu M.D.
Consultant
ATXI stock traded closed the last session at $0.263, which is $0.00 or 1.23% lower than its previous close of $0.26. ATXI's current trading price is 31.60% lower than its 52-week high of $2.65 where as its distance from 52-week low of 0.20% is -90.07%.
Number of ATXI employees currently stands at -. ATXI operates from 1140 Avenue of the America, 9th Floor, New York, NY 10036, United States.
Official Webiste of $ATXI is: https://www.avenuetx.com
ATXI could be contacted at ATXI operates from 1140 Avenue of the America, 9th Floor, New York, NY 10036, United States, or at phone #781 652 4500 and can also be accessed through its website.
ATXI stock volume for the day was 355,970 shares while in the previous session number of ATXI shares traded was 355,970 . The average number of ATXI shares traded daily for last 3 months was 339.37 Thousands.
The percentage change in ATXI stock occurred in the recent session was 1.23% while the dollar amount for the price change in ATXI stock was $0.00.
In the recent session, the day high for ATXI stock was $0.272 while the low for ATXI stock touched on the day was $0.25.
The market value of ATXI currently stands at 6.16 Million with its latest stock price at $0.26 and 20.96 Million of its shares outstanding.